All In Biotech

Drug Trial Radar · NCT00023244

Steroid Withdrawal in Pediatric Kidney Transplant Recipients

A Double-Blind Randomized Trial of Steroid Withdrawal in Sirolimus- and Cyclosporine-Treated Primary Transplant Recipients

Last checked: Nov 19, 2026Latest source record: Oct 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 274 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

274

Actual

Start

Jan 2001

Primary completion

Jun 2005

Study completion Jun 2005

Sponsor

Sponsor type
NIH
Collaborators
Cooperative Clinical Trials in Pediatric Transplantation
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 1 day, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to examine the effects of withdrawing steroids on graft rejection and kidney functions in kidney transplant recipients between the ages of 0 and 20 years (prior to their 21st birthday). Graft survival has improved in recent years in children with kidney transplants. One bad side effect of steroid maintenance therapy has been growth retardation. Doctors believe steroids might be safely withdrawn in patients that are receiving other maintenance therapies. If steroids are removed, children might catch up in their growth and also might have fewer side effects of other kinds. This study evaluates whether steroid therapy can be withdrawn in a way that does not increase graft rejection.

Conditions

  • End-Stage Renal Disease

Interventions

  • BasiliximabDrug

    Administered as a bolus intravenous injection. The first dose is given pre-operatively, the second dose is given on post-transplant day four. Dosage is determined by individual weight.

  • CyclosporineDrug

    Participants receiving cyclosporine microemulsion formula (in lieu of tacrolimus) will have the dose adjusted to maintain a whole blood trough Abbott TDx assay monoclonal level of 175-400 ng/mL (or an equivalent high pressure liquid chromatography (HPLC) level) for the first 2 weeks after transplant. The dose will subsequently be tapered to maintain a trough level of 175-300 ng/mL from week 3 to month 3, and 50-250 ng/mL from month 3 through the end of the study at month 36 (year 3).

  • TacrolimusDrug

    Participants receiving tacrolimus (in lieu of Cyclosporine) will have the dose adjusted to maintain a whole blood trough level between 10 and 15 ng/mL for the first 4weeks after transplant. Trough levels will be maintained between 5 and 10 ng/mL thereafter throughout the duration of the study.

  • SirolimusDrug

    Participants take daily (orally, either as tablets or as liquid) starting on postoperative day 1 at a dose of 6 mg/m2 and will be adjusted to maintain a trough level of 10-20 ng/mL throughout the study.

  • MethylprednisoloneDrug

    Administered at 10 mg/kg intravenously perioperatively and on postoperative day 1.

  • PrednisoneDrug

    Administered orally beginning on Post-Op Day 2 and maintained for all participants until day 180. Randomization will determine whether patients will maintain this treatment following day 180.

  • BactrimDrug

    All subjects will receive TMP SMX (Bactrim), pneumocystis jiroveci (carinii) prophylaxis, beginning on postoperative day 1 and continuing for 6 months following transplant. Dosage: 10 mg/kg taken orally three times weekly (maximum dose 160 mg).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Growth, measured as change in standardized height from 6 month to 2.5 years post-transplantationTime frame: At 6 months and 2.5 years post-transplant

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • UCSD Medical Center

    San Diego, California

  • Denver Children's Hospital

    Aurora, Colorado

  • University of Florida Health Science Center

    Jacksonville, Florida

  • Emory Children's Center

    Atlanta, Georgia

  • Tulane University Medical Center

    New Orleans, Louisiana

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Children's Hospital of Boston

    Boston, Massachusetts

  • University of New Mexico Health Science Center

    Albuquerque, New Mexico

  • The Children's Hospital of Buffalo

    Buffalo, New York

  • Westchester Medical Center

    Valhalla, New York

  • Rainbow Babies and Childrens Hospital

    Cleveland, Ohio

  • University Hospitals of Cleveland

    Cleveland, Ohio

  • Penn State College of Medicine

    Hershey, Pennsylvania

  • LeBonheur Children's Medical Center

    Memphis, Tennessee

  • Christopher Goldsbury Center

    San Antonio, Texas

  • Children's Hospital and Regional Medical Center

    Seattle, Washington

  • University of Wisconsin

    Madison, Wisconsin

  • Hospital Infantil de Mexico

    Mexico City, Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.